During the 12th Five-Year Plan, the top 100 new drug companies will increase their sales to 50%

"The "12th Five-Year Plan" national strategic emerging industries development plan" divided the bio-industry into four sections: bio-pharmaceutical industry, bio-medical engineering industry, bio-agricultural industry and bio-manufacturing industry. It proposes that efforts will be made to achieve an average annual growth of over 20% in the industrial scale during the 12th Five-Year Plan period, and that the output value of the biological industry will reach 4 trillion yuan by the end of the “Twelfth Five-Year Plan” period, of which the total output value of the biomedical industry will be as high as 3.6 trillion.

"Planning" proposes that by 2015, a batch of international drug development platforms represented by genetic engineering drugs, new vaccines, antibody drugs, new chemical drugs, modern Chinese medicine, etc. will be formed, and the development level of pharmaceutical technology and equipment will be greatly enhanced. More than 30 new drugs with independent intellectual property rights were put on the market, and more than 200 pharmaceutical preparations entered the international mainstream market, and the degree of industrial concentration increased significantly.

According to industry experts, biomedicine will focus on innovative drug types such as biotechnology drugs, new vaccines, diagnostic reagents, and chemical drugs for the prevention and treatment of major diseases in the next five years. Wang Changlin, director of the Industrial Development Institute of the Macroeconomic Research Institute of the National Development and Reform Commission, predicts that by 2015, the sales revenue of the top 100 new drug companies will account for 50% of the total sales revenue of the industry; by 2020, five companies will enter the top 100 pharmaceutical companies in the world.

At present, biopharmaceuticals have the most attention in three major areas: vaccine industry, genetic engineering, and monoclonal antibodies. The listed company Tiantan Biotech is a leading manufacturer of vaccines, and Hua Lan Bio and Zhifei Bio are not to be underestimated. Among them, Zhifei’s own products are numerous, and the sales volume of vaccine products in the past three years accounted for 10.99% of the second-class vaccine market in China respectively. The share of 11.13% and 10.78% was ranked first among private vaccine companies.

Companies involved in genetic engineering include the leading company in the restructuring of protein, the Changchun High-tech subsidiary Kinsey Pharmaceuticals, and the leading domestic biological pharmaceutical company Shuanglu Pharmaceutical. Lansen Co., Ltd.'s CITIC Guojian is a leader in the domestic monoclonal antibody industry. It has the first domestic monoclonal antibody "Yisipu" and more than ten varieties in research, leading domestic research and development capabilities; In addition, Hisun Pharmaceutical, Livzon Group, Health Yuan, etc. are involved in the field of monoclonal antibody drugs.